Galapagos N.V./  BE0003818359  /

Galapagos N.V. is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Their pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. Galapagos’ mission is to develop first-in-class medicines based on the discovery of novel targets. Using human primary cells and patient cells, the company discovers which proteins (‘targets’) play a key role in causing diseases such as rheumatoid arthritis, inflammatory bowel disease and fibrosis. Galapagos then aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease. This approach addresses the root cause of the disease rather than just treating the symptoms. The Galapagos group, including fee-for-service subsidiairy Fidelta, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France and Croatia.